Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152)

by Keizer, Ron J., Zandvliet, Anthe S., Beijnen, Jos H., Schellens, Jan H. M., Huitema, Alwin D. R.
Published 2011

Evaluation of α2-Integrin Expression as a Biomarker for Tumor Growth Inhibition for the Investigational Integrin Inhibitor E7820 in Preclinical and Clinical Studies

by Keizer, Ron J., Funahashi, Y., Semba, T., Wanders, J., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R.
Published 2011

Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses

by Keizer, Ron J, Jansen, Robert S, Rosing, Hilde, Thijssen, Bas, Beijnen, Jos H, Schellens, Jan H M, Huitema, Alwin D R
Published 2015

Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

by Soto, Elena, Keizer, Ron J., Trocóniz, Iñaki F., Huitema, Alwin D. R., Beijnen, Jos H., Schellens, Jan H. M., Wanders, Jantien, Cendrós, Josep María, Obach, Rosendo, Peraire, Concepción, Friberg, Lena E., Karlsson, Mats O.
Published 2010